Although some metabolic rate‐limiting enzymes (i.e. IDH1 and CPS1) demonstrated higher mutation rates in parts of cancer types, most metabolic rate‐limiting enzymes had lower mutation rates in Pan‐cancer human cancers (Figure 2D). This evidence concerns the gene CPS1 and polyarteritis nodosa.